Tonix Pharmaceuticals to present new data on mpox and smallpox vaccine candidate

Tonix Pharmaceuticals (TNXP) announced the presentation of new findings on TNX-801 – recombinant horsepox, live virus vaccine – at the Vaccine Congress 2025 in Vienna July 10. “The data show that TNX-801 can deliver durable immunity while remaining highly attenuated, a balance that sets it apart from earlier orthopox vaccines,” said CEO Seth Lederman. “The novel finding that subcutaneous, or s.c., administration of TNX-801 provides equivalent protection to percutaneous administration, is leading us to develop the s.c. product first…We believe TNX-801 has the potential to become a critical tool for containing mpox and preparedness against the malicious reintroduction of smallpox.” Preclinical studies further showed that a single dose of TNX-801 produced strong binding and neutralizing antibody responses across mice, rabbits, hamsters, and cynomolgus macaques, including immunocompromised animals. All vaccinated macaques survived lethal Clade I mpox challenge without lesions, and rabbit models remained fully protected for fourteen months.